TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29065076

Group type: EXPERIMENTAL
Intervention: Low-load circuit resistance training protocol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 42
Study: 24526184

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23986963

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine (CHX) rinse
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Essential oil rinse containing ethanol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Essential oil rinse without ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 12
Study: 21055739

Group type: EXPERIMENTAL
Intervention: CDB-2914 (10 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CDB-2914 (20 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CDB-2914 (10 mg) and CDB-2914 (20 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 26
Study: 18204878

Group type: EXPERIMENTAL
Intervention: Durasphere anal injection (mean of 8.8 ml injected)
Number of subjects: 33
Study: 17154744

Group type: EXPERIMENTAL
Intervention: Active high-dose (35 mg) 24-hr patches
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 14585863

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 217

Group type: COMPARATOR
Intervention: Ciprofloxacin plus amoxicillin
Number of subjects: 217
Study: 11105974

Group type: EXPERIMENTAL
Intervention: Whole-body restrictions (6 single restrictions at two severity levels and 2 multiple restrictions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrestricted control
Number of subjects: 0
Study: 9055918

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 1 IU/kg/week, administered subcutaneously once daily
Number of subjects: 203

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 203
Study: 1841830

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (ivIgG) for prophylaxis of infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (ivIgG)
Number of subjects: 0
Study: 6357269

Group type: EXPERIMENTAL
Intervention: Stilboestrol therapy (mean dose of about 11.5 g starting at the 12th week of pregnancy)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Control group (placebo tablets)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Stilboestrol therapy
Number of subjects: 650
Study: 31818692

Group type: EXPERIMENTAL
Intervention: Statin + CoQ10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin + Placebo
Number of subjects: 0
Study: 30590472

Group type: EXPERIMENTAL
Intervention: Web-based intervention focused on NMUPD
Number of subjects: 391

Group type: COMPARATOR
Intervention: General health website
Number of subjects: 391
Study: 28623122

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin-Pemetrexed
Number of subjects: 0
Study: 27927226

Group type: EXPERIMENTAL
Intervention: Medical clearance required for higher-risk individuals
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Lower-risk individuals
Number of subjects: 1244
Study: 25068207

Group type: EXPERIMENTAL
Intervention: Non-cellulose dried matrix spotting (DMS) cards
Number of subjects: 49

Group type: COMPARATOR
Intervention: Filter paper (FP)
Number of subjects: 49
Study: 22843087

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with bevacizumab
Number of subjects: 850

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin without bevacizumab
Number of subjects: 850
Study: 19288755

Group type: EXPERIMENTAL
Intervention: Qiantongding Decoction
Number of subjects: 70

Group type: COMPARATOR
Intervention: Indometacin (Control)
Number of subjects: 70
Study: 17311979

Group type: EXPERIMENTAL
Intervention: Probiotics (various strains including Lactobacillus rhamnosus GG, L. reuteri, L. casei, L. acidophilus, Escherichia coli strain Nissle 1917, certain bifidobacteria, Enterococcus faecium SF68, Saccharomyces boulardii)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 0
Study: 15081569

Group type: EXPERIMENTAL
Intervention: ximelagatran 30 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ximelagatran 60 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: r-hirudin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 120

Group type: COMPARATOR
Intervention: control (tap water)
Number of subjects: 120
Study: 12674781

Group type: EXPERIMENTAL
Intervention: Acoustical technique measuring transmission properties of acoustic waves in the hip joints
Number of subjects: 87
Study: 9825816

Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 216
Study: 7695954

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 50
Study: 2577382

Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no OK-432)
Number of subjects: 36
Study: 4364175

Group type: EXPERIMENTAL
Intervention: Isoprinosine (6 g daily for 7 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31782535

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 88
Study: 31288902

Group type: EXPERIMENTAL
Intervention: Pharmacist counseling
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 19
Study: 28161530

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (60,000 IU/month or 120,000 IU/month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (18,000 IU/month)
Number of subjects: 0
Study: 25023847

Group type: EXPERIMENTAL
Intervention: Strontium ranelate formulation A (2g)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Strontium ranelate formulation B (2g)
Number of subjects: 50
Study: 22836732

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 208
Study: 21924709

Group type: EXPERIMENTAL
Intervention: Increased elaboration of components in explanations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental manipulation of elaboration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technical elaboration
Number of subjects: 0
Study: 19750190

Group type: EXPERIMENTAL
Intervention: MOBILE-Self-Monitored
Number of subjects: 17

Group type: COMPARATOR
Intervention: MOBILE-Coached
Number of subjects: 17

Group type: COMPARATOR
Intervention: MOBILE-Coached and MOBILE-Self-Monitored
Number of subjects: 17
Study: 16508278

Group type: EXPERIMENTAL
Intervention: 150 mmol/l calcium lactate prerinse
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 30 mmol/l calcium lactate prerinse
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 300 mmol/l calcium lactate prerinse
Number of subjects: 5

Group type: COMPARATOR
Intervention: NaF control without a prerinse
Number of subjects: 5
Study: 12861344

Group type: EXPERIMENTAL
Intervention: 10% Pentastarch infusion (500 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% saline (60 ml) placebo infusion
Number of subjects: 12
Study: 11060526

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIgG), 1 g/kg body weight, given on days 0, 3, 7, 14, and 21
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Not applicable (comparison group with IgG levels >4 g/L)
Number of subjects: 81
Study: 9863128

Group type: EXPERIMENTAL
Intervention: Sini decoction (n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: PTCA only (n = 23)
Number of subjects: 46
Study: 8307341

Group type: EXPERIMENTAL
Intervention: Meditation-based stress reduction program
Number of subjects: 77
Study: 3520708

Group type: EXPERIMENTAL
Intervention: B-15000 (new non-ionic contrast medium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isteropac (traditional ionic contrast medium)
Number of subjects: 0
Study: 29725191

Group type: EXPERIMENTAL
Intervention: SISTAS intervention (12 weekly classes followed by nine monthly booster sessions)
Number of subjects: 337
Study: 27244210

Group type: EXPERIMENTAL
Intervention: Autologous bone from the iliac crest region (n=4)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Recombinant human bone morphogenetic protein-2 (rhBMP-2) (n=8)
Number of subjects: 12
Study: 24931702

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: sICAM-1
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: sVCAM-1
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Models including novel biomarkers
Number of subjects: 1345
Study: 22673035

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (n=17), 12 sessions of 40 minutes each, three days/week for four weeks.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Physical Therapy (n=17), 12 sessions of 40 minutes each, three days/week for four weeks.
Number of subjects: 34
Study: 20206581

Group type: EXPERIMENTAL
Intervention: sTMS (single-pulse transcranial magnetic stimulation)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 201

Group type: COMPARATOR
Intervention: sTMS and Sham stimulation
Number of subjects: 201
Study: 18793543

Group type: EXPERIMENTAL
Intervention: Cystatin C formula (GFR = 90.63 x cystatin C‐1.192)
Number of subjects: 592

Group type: COMPARATOR
Intervention: MDRD formula
Number of subjects: 592

Group type: COMPARATOR
Intervention: CG formula
Number of subjects: 592
Study: 16241919

Group type: EXPERIMENTAL
Intervention: Dietary treatment and regular monitoring (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Standard management (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 300
Study: 12362930

Group type: EXPERIMENTAL
Intervention: Riamet (artemether-lumefantrine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Quinine (10 mg/kg body weight, intravenous infusion)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Riamet + Quinine
Number of subjects: 42
Study: 10102765

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7587918

Group type: EXPERIMENTAL
Intervention: Multiple insulin injection treatment (MIT) group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional insulin injection treatment (CIT) group
Number of subjects: 110
Study: 1971955

Group type: EXPERIMENTAL
Intervention: 15 or 30 mg flurazepam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.25 or 0.50 mg triazolam
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo at bedtime
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo in the morning
Number of subjects: 80
Study: 922640

Group type: EXPERIMENTAL
Intervention: Alpha feedback
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alpha, EMG, or joked feedback
Number of subjects: 75

Group type: COMPARATOR
Intervention: No-feedback or no-treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 75
Study: 30879734

Group type: EXPERIMENTAL
Intervention: Late initiation of supplemental parenteral nutrition (PN) after one week
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Early initiation of supplemental parenteral nutrition (PN) within 24 hours
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Weight Z‐score increase
Number of subjects: 1440
Study: 31711543

Group type: EXPERIMENTAL
Intervention: Free text analysis using the Freetext Matching Algorithm
Number of subjects: 3800
Study: 27964826

Group type: EXPERIMENTAL
Intervention: UC-MSC treatment (1.0 × 10^6 MSCs per kg body weight, six doses through peripheral intravenous infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: UC-MSC treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional therapeutic protocol (control group)
Number of subjects: 12
Study: 25244977

Group type: EXPERIMENTAL
Intervention: ESwab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Multi-sample method
Number of subjects: 80
Study: 23279308

Group type: EXPERIMENTAL
Intervention: Text plus a visual image of predicted internal body fat (image arm)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Solely text form (control arm)
Number of subjects: 901
Study: 21771279

Group type: EXPERIMENTAL
Intervention: Internet-based psychological treatment program (Revive) consisting of communication skills training, sensate focus exercises, and regular contact with a therapist
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study: 18453491

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16534755

Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA at 2.5 micromol/kg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA at 5.0 micromol/kg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA at 7.5 micromol/kg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA (all doses)
Number of subjects: 113
Study: 14635462

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a grass extract (ALK‐Abellò)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11037741

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 766

Group type: COMPARATOR
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study: 8957141

Group type: EXPERIMENTAL
Intervention: Enhanced day treatment program plus abstinent contingent work therapy and housing (EC)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 176
Study: 1568426

Group type: COMPARATOR
Intervention: 10 mg quinapril (single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10 mg quinapril twice daily for 14 days
Number of subjects: 16
Study: 3894337

Group type: EXPERIMENTAL
Intervention: Molindone (injection for 2-3 days, then oral for up to 4 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Haloperidol (injection for 2-3 days, then oral for up to 4 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both drugs (Molindone and Haloperidol)
Number of subjects: 35
Study: 30209956

Group type: EXPERIMENTAL
Intervention: 3D-FSE-Cube-Flex MRD
Number of subjects: 21

Group type: COMPARATOR
Intervention: 3D-FSE-Cube
Number of subjects: 21
Study: 30268156

Group type: EXPERIMENTAL
Intervention: Dendritic cell intradermal vaccinations (two courses of four daily doses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 19
Study: 27352491

Group type: EXPERIMENTAL
Intervention: Oblique insertion therapy at anatomical points
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional acupuncture with perpendicular insertion
Number of subjects: 80
Study: 24212124

Group type: EXPERIMENTAL
Intervention: 3‐month exercise intervention (160 min·wk of moderate‐intensity aerobic walking, twice weekly resistance training with resistance bands)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 3‐month exercise intervention
Number of subjects: 46
Study: 22950925

Group type: EXPERIMENTAL
Intervention: Treatment group (exposed to video, audio, and print advertisements promoting parent-child communication about delaying sexual activity)
Number of subjects: 1969

Group type: COMPARATOR
Intervention: Control group (not exposed to the treatment messages)
Number of subjects: 1969
Study: 20230859

Group type: EXPERIMENTAL
Intervention: Glucose administration (dose not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-task performance (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose administration (regardless of dose or dual-task conditions)
Number of subjects: 0
Study: 16832224

Group type: EXPERIMENTAL
Intervention: Monetary incentive ($100 for 15% reduction in LDL-C)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational program
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 171
Study: 12721177

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10831772

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 9203099

Group type: EXPERIMENTAL
Intervention: Group A (smoother surface with Ra ≤ 0.088 microns and Rz ≤ 1.027 microns)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Group B (rougher surface)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Group C (roughest surface)
Number of subjects: 8
Study: 8466238

Group type: EXPERIMENTAL
Intervention: Nebulised budesonide suspension
Number of subjects: 36
Study: 3535714

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30695078

Group type: EXPERIMENTAL
Intervention: Mobile phone app providing ACH antibiotic guidelines
Number of subjects: 436
Study: 29459120

Group type: EXPERIMENTAL
Intervention: Lumbar core stabilization exercise (LCSE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo condition (passive cycling in crook lying)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control condition (positioning in crook lying and rest)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 24
Study: 26929085

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 24216616

Group type: EXPERIMENTAL
Intervention: fampridine-SR 25 mg twice daily
Number of subjects: 415

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 415
Study: 21882176

Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg orally 5 days per week
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acitretin
Number of subjects: 70
Study: 20423422

Group type: EXPERIMENTAL
Intervention: Relaxation training programme
Number of subjects: 121

Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 121
Study: 18157419

Group type: EXPERIMENTAL
Intervention: Right atrial (RA) pacing group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non‐pacing (NP) group
Number of subjects: 160
Study: 16736131

Group type: EXPERIMENTAL
Intervention: Intensive glucose and tight blood pressure control policies
Number of subjects: 4320

Group type: COMPARATOR
Intervention: Glycaemia control (HbA(1c) <6.0%) and blood pressure control (SBP <130 mmHg)
Number of subjects: 4320

Group type: COMPARATOR
Intervention: Glycaemia control (HbA(1c) > or =8%) and blood pressure control (SBP > or =150 mmHg)
Number of subjects: 4320

Group type: EXPERIMENTAL
Intervention: Updated mean HbA(1c) decrement
Number of subjects: 4320

Group type: EXPERIMENTAL
Intervention: Updated mean SBP decrement
Number of subjects: 4320
Study: 12686922

Group type: EXPERIMENTAL
Intervention: Arthroscopic eminoplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional open eminectomy
Number of subjects: 24
Study: 10898316

Group type: EXPERIMENTAL
Intervention: Autologous blood clot
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gelfoam
Number of subjects: 100
Study: 9184881

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt performed within 8 hr of initial contact (21 patients)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt in survivors (22 patients)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt
Number of subjects: 43

Group type: COMPARATOR
Intervention: Emergency medical therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Emergency medical therapy and elective shunt
Number of subjects: 43
Study: 7682261

Group type: EXPERIMENTAL
Intervention: Aspirin 60-80 mg/kg alone (Group A)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Aspirin plus intravenous gamma globulin (IVGG) 400 mg/kg for 5 days (Group B)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Aspirin plus a single dose of IVGG 2.0 gm/kg (Group C)
Number of subjects: 293
Study: 3105568

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 30
Study: 28715141

Group type: EXPERIMENTAL
Intervention: Walnut consumption for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo consumption for 5 days
Number of subjects: 10
Study: 27198484

Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 90% resting motor threshold)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 25
Study: 24902402

Group type: EXPERIMENTAL
Intervention: ABR - 3x/day-1 minute toothbrushing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ERO - 3x/day - 5 minutes extraoral immersion into regular Coca Cola
Number of subjects: 13

Group type: COMPARATOR
Intervention: CONT - control (no challenge)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ERO+ABR - erosive protocol followed by a 1-minute toothbrushing
Number of subjects: 13
Study: 22551107

Group type: EXPERIMENTAL
Intervention: EDP plus mitotane
Number of subjects: 304

Group type: COMPARATOR
Intervention: Streptozocin plus mitotane
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: EDP plus mitotane (second-line therapy)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Streptozocin plus mitotane (second-line therapy)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: EDP plus mitotane (first-line therapy, no second-line therapy)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Streptozocin plus mitotane (first-line therapy, no second-line therapy)
Number of subjects: 304